MRI/TRUS fusion biopsies in men with PSA values < 5.2 ng/ml

There is a distinctly “odd” paper in the December 2014 issue of the Journal of Urology on optimization of the use of MRI/TRUS fusion-guided biopsies in men suspected of having prostate cancer. … READ MORE …

The Prostate Health Cocktail in management of biochemically recurrent prostate cancer

A newly published paper by some highly regarded researchers provides data from a small, Phase II trial of Prostate Health Cocktail (PHC) — an “over-the-counter” combination herbal supplement — in the management of biochemical recurrence of prostate cancer. … READ MORE …

Which patients with a PSM post-surgery need early adjuvant therapy?

Could more intensive monitoring of PSA levels in the first few months after a radical prostatectomy help to determine which patients who have a positive surgical margin (PSM) need adjuvant radiation therapy and which don’t? … READ MORE …

What a young primary care opinion leader thinks about screening for prostate cancer

In a guest blog post, published yesterday on the MedPage Today web site, Dr. Andrew Buelt, a co-producer of the “Questioning Medicine” podcast for physicians, takes on the issue of screening for prostate cancer. … READ MORE …

D’Amico on the individualization of prostate cancer risk management

In an interesting article in the September 2014 issue of The ASCO Post, Dr. Anthony D’Amico argues in favor of a future in which individualized approaches to risk will replace PSA screening alone as a means of determining who actually needs to be biopsied and (if necessary) receive treatment for clinically significant prostate cancer. … READ MORE …

To quest and test (or not to quest at all)

On The New York Times‘s “Well” blog site today. Dr. Barak Gaster takes on the complex issue of how doctors need to get better at talking to patients about the pros and cons of PSA testing. And there very definitely are pros and cons! I kid you not.

ERSPC mortality data at 13 years of follow-up published

The Lancet has just published previously reported data from the European Randomized Study of Screening for Prostate Cancer (the ERSPC trial) at 13 years of follow-up. These data were first reported earlier this year at the annual meeting of the EAU, and we commented then on the significance of these data. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,175 other followers